The in vivo efficacy of the PAM inhibitors was tested in two different mini-PDX BC models, one with PIK3CA/PTEN mutations and one lacking PIK3CA/PTEN alterations (Fig. 7a). This evidence concerns the gene PIK3CA and breast cancer.